Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:01:27.695Z.
Calculation as of: 2026-10-06T19:01:27.695Z.
Quote observation: 2026-10-06T19:00:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$415.78M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$411.43M
EV/FCF Ratio
N/A
TTM Avg
196.27x
3Y Avg
196.27x
5Y Avg
196.27x
Market Cap
$423.83M
EV/FCF Ratio
N/A
TTM Avg
32.08x
3Y Avg
32.08x
5Y Avg
32.08x
Market Cap
$426.51M
EV/FCF Ratio
N/A
TTM Avg
98.46x
3Y Avg
98.46x
5Y Avg
98.46x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $415.78M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $417.10M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $414.45M | N/A | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.43M | N/A | 196.27x | 196.27x | 196.27x |
| Prothena Corporation plc (PRTA)vs › | $423.83M | N/A | 32.08x | 32.08x | 32.08x |
| Rezolute, Inc. (RZLT)vs › | $407.80M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $409.04M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | 98.46x | 98.46x | 98.46x |
| Tilray Brands, Inc. (TLRY)vs › | $426.64M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $406.55M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
